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Abstract
Schizophrenia is a highly heritable condition, as demonstrated in family, twin and adoption studies. Candidate
genes from the dopaminergic system have long been hypothesized to be involved in the etiology of this disorder. In
the present study, we investigated the genetic association between polymorphisms in the D2 and D3 dopamine
receptor (DRD2, DRD3) genes and schizophrenia. We examined 90 trios from Portugal, and negative results were
obtained from association studies with both Haplotype Relative Risk (HRR) and Transmission Disequilibrium Test
(TDT), as well as TRANSMIT. Therefore, we conclude that neither the DRD2 nor the DRD3 gene polymorphisms
investigated are associated with schizophrenia in our sample.
 2004 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
Schizophrenia is a complex genetic disorder that
affects approximately 1% of the worldwide popu-
lation. Despite extensive research efforts for many
years, no mutations or disease-predisposing DNA
sequence variations have been identified. The
mode of inheritance of schizophrenia is likely to
be polygenicymultifactorial (McGuffin et al.,
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1995), and association studies are the most impor-
tant strategies to investigate the candidate genes
implicated in this disorder.
Although the biological basis of schizophrenia
is unknown, dopamine is considered to be the
main neurotransmitter implicated in this disease,
and genes involved in dopaminergic pathways are
being studied as candidate genes for schizophrenia.
Five distinct subtypes of G-protein-coupled dopa-
mine receptors mediate the actions of dopamine,
three of which belong to the dopamine D2 family:
the dopamine D2 receptor (DRD2), the dopamine
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D3 receptor (DRD3) and the dopamine D4 recep-
tor (DRD4) (for review, see Missale et al., 1998).
The DRD2 is expressed in both limbic and caudate
areas and is a target of all antipsychotic drugs.
These characteristics make the DRD2 gene an
interesting candidate for schizophrenia. The human
DRD2 and DRD3 genes were cloned and are
localized to chromosome 11q22–q23 (Grandy et
al., 1989) and chromosome 3q13.3 (Le Coniat et
al., 1991), respectively. The DRD3 gene is struc-
turally related to the DRD2 gene and was sug-
gested to be a favored candidate gene for
schizophrenia because it is selectively expressed
in the limbic areas, which are associated with
cognitive, emotional, and endocrine functions
(Sokoloff et al., 1990). The TaqI-A and Ser311Cys
polymorphisms located in the 39 flanking region
and in the coding region of the DRD2 gene,
respectively, and the Ser9Gly polymorphism locat-
ed in the coding region of DRD3 may be directly
or indirectly implicated in schizophrenia through
dopaminergic or other systems (Carlsson et al.,
2001). Genetic variation in these genes might
account for interindividual differences in response
to drugs. Moreover, alterations in genes coding for
receptor proteins as, for example, DRD2 and
DRD3, may affect their binding affinities for
neuroleptics, the efficiency of signal transduction,
or their levels of expression, which may in turn
alter the drug’s therapeutic action.
Several case–control studies have investigated
the possible involvement of the DRD2 and DRD3
genes in schizophrenia, but the results are incon-
clusive (Dubertret et al., 1998; Spurlock et al.,
1998; Williams et al., 1998; Kremer et al., 2000;
Hori et al., 2001; Himei et al., 2002; Morimoto et
al., 2002). However, meta-analyses have recently
supported the involvement of the DRD2 and
DRD3 genes in the pathogenesis of schizophrenia
(Jonsson et al., 2003a,b). Thus, more independent¨
family association studies are required, mainly
using a homogeneous population as, for example,
the Portuguese population (Schindler et al., 1999).
In the present study, we investigated the possible
involvement of polymorphisms of the DRD2 and
DRD3 genes in schizophrenia by using family
association studies in a Portuguese population.
2. Methods
2.1. Subjects
The sample used in this study consisted of 90
unrelated schizophrenic patients from Azores and
Mainland, Portugal (58 males and 32 females) and
their parents, for a total of 270 individuals. All of
the subjects were Caucasian and ethnically Portu-
guese. Approval was obtained from local ethics
committees, and informed consent was given by
all subjects. All patients were administered the
Diagnostic Interview for Genetics Studies (DIGS),
rated with the Operational Criteria checklist
(OPCRIT), and all were diagnosed according to
DSM-IV. Blood samples were collected with
EDTA as anticoagulant, and genomic DNA was
prepared using the standard method (Miller et al.,
1988).
2.2. Laboratory methods
2.2.1. DRD2 gene polymorphisms
The amplification of the TaqI-A polymorphism
of the DRD2 gene was carried out according to
the method described by Grandy et al. (1993),
with some modifications. A total of 100 ng genom-
ic DNA was amplified by polymerase chain reac-
tion (PCR) in a volume of 25 ml containing 200
mM dNTPs, 1 mM of each primer, 1=reaction
buffer, 1.5 mM MgCl , and 1 unit of Taq poly-2
merase. After initial denaturation at 94 8C for 5
min, 30 cycles of PCR reaction were performed
under the following conditions: denaturation at 94
8C, 1 min, annealing at 56 8C, 1 min, and extension
at 72 8C, 1 min. Amplification products were
digested with TaqI restriction enzyme at 65 8C,
and separated by electrophoresis in a 2% Metaphor
(FMC BioProducts, Portugal) agarose gel, and
visualized with ethidium bromide staining under
ultraviolet light.
The Ser311Cys polymorphism of the DRD2
gene was investigated by PCR, using the protocol
described by Arinami et al. (1994), with some
modifications. The amplification was performed in
a final volume of 25 ml, containing 100 ng
genomic DNA as template, 200 mM dNTPs, 0.2
pmol of each primer, 10 mM Tris–HCl (pH 8.3),
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Table 1
HRR and TDT results for two individual TaqI-A and Ser311Cys polymorphisms of DRD2 gene in Portuguese schizophrenic trios
DRD2 gene
Transmitted Not-transmitted x (d.f.s1), P-value2
HRR
TaqIA1 79 76 x s0.045, Ps0.8312
TaqIA2 101 104
Cys311 4 2 x s0.169, Ps0.6812
Ser311 176 178
TDT
TaqIA1 72 69 x s0.064, Ps0.8002
TaqIA2 69 72
Cys311 4 2 x s0.667, Ps0.4142
Ser311 2 4
2.0 mM MgCl , and 1 unit of Taq polymerase.2
PCR amplification was initiated at 94 8C for 5
min and performed for 30 cycles each consisting
of 94 8C for 30 s, 66 8C for 30 s, and 72 8C for
30 s. PCR products were digested using enzyme
Sau96I. The digested fragments were separated in
3.5% agarose gel and were visualized by ethidium
bromide staining.
2.2.2. DRD3 gene polymorphism
The analysis of the Ser9Gly polymorphism of
the DRD3 gene was carried out by using a PCR-
based restriction analysis according to the method
described by Lannfelt et al. (1992), with slight
modifications. The PCR was carried out in a total
volume of 25 ml containing 100 ng genomic DNA
as template, 100 mM dNTPs, 0.4 pmol of each
primer, 10 mM Tris–HCl (pH 8.3), 1.5 mM
MgCl , 0.01% gelatine and 1.5 unit of Taq poly-2
merase. After initial denaturation at 95 8C for 5
min, 35 cycles of PCR reaction were performed
under conditions of denaturation at 95 8C for 30
s, annealing at 56 8C for 30 s, and extension at 72
8C for 30 s. Amplification products were digested
with MscI restriction enzyme, separated by elec-
trophoresis in a 3.5% agarose gel, and visualized
with ethidium bromide staining under ultraviolet
light.
2.3. Statistical analysis
In this study, the association analysis was per-
formed with 90 nuclear families with one proband
(trios), and two strategies were used, the Haplo-
type Relative Risk (HRR) (Terwilliger and Ott,
1992), and Transmission Disequilibrium Test
(TDT) (Spielman et al., 1993; Spielman and
Ewens, 1998). We used the HRR and TDT to
avoid any potential population stratification. In
these methods, the non-transmitted parental alleles
were used as ‘controls’ to evaluate allele transmis-
sion. The TDT-STDT program (v 1.1) uses data
from heterozygous parents only, and tests for
individual markers. Furthermore, multiple marker
haplotype transmission was performed with pro-
gram TRANSMIT v2.5 (Clayton, 1999). The pro-
gram TRANSMIT tests for association between
markers and disease, examining the transmission
of multilocus haplotypes.
3. Results
We investigated the relationship between some
polymorphisms at DRD2 and DRD3 genes and
schizophrenia. Genotypes were obtained from 90
Portuguese schizophrenic patients and their par-
ents. In association analysis we used HRR and
TDT methods to test if the marker locus and the
hypothetical disease locus were linked or in link-
age disequilibrium. Table 1 presents the results of
HRR and TDT analysis for the individual markers
(TaqI-A, Ser311Cys) at the DRD2 gene. When
the HRR design was used, no significant differ-
ences were observed between transmitted and non-
transmitted alleles for both polymorphisms of the
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Table 3
HRR and TDT results for individual Ser9Gly polymorphism
of the DRD3 gene in Portuguese schizophrenic trios
DRD3 gene
Transmitted Not-transmitted x (d.f.s1), P-value2
HRR
Ser9 122 126 x s0.117, Ps0.7332
Gly9 58 54
TDT
Ser9 35 39 x s0.216, Ps0.6422
Gly9 39 35
Table 2
Estimated haplotype probabilities and chi-square test of transmission of multi-marker haplotypes at the DRD2 gene using
TRANSMIT
DRD2 gene
Haplotypes Obs Exp O–E Frequency Haplotypic P-value
TaqIA2yCys311 4 3 1.5 0.017 0.414
TaqIA1ySer311 79 77.5 35.25 0.430 0.801
TaqIA2ySer311 97 99.5 34.75 0.179 0.672
DRD2 gene (TaqI-A polymorphism: x s0.045,2
d.f.s1, Ps0.831; Ser311Cys polymorphism: x s2
0.169, d.f.s1, Ps0.681).
With TDT analysis no significant transmission
disequilibrium between the alleles of the DRD2
gene and schizophrenia was found (TaqI-A poly-
morphism: x s0.064, d.f.s1, Ps0.800;2
Ser311Cys polymorphism: x s0.667; Ps0.414;2
see Table 1). The haplotypes of paired markers for
transmission disequilibrium were analyzed by
using TRANSMIT, and no evidence for linkage
disequilibrium was observed (Table 2).
Relative to the DRD3 gene, using the HRR and
the TDT designs, we found no evidence for asso-
ciation and linkage disequilibrium between the
Ser9Gly polymorphism and schizophrenia (HRR:
x s0.117, d.f.s1, Ps0.733; TDT: x s0.216,2 2
d.f.s1, Ps0.642; Table 3).
4. Discussion
In complex disorders like schizophrenia, various
susceptibility genes are considered to be involved
in etiology. Family-based association studies are
an appropriate way to explore the putative contri-
bution of candidate genes. Concerning molecular
genetic studies, schizophrenia is one of the most
extensively studied brain disorders, and attention
has been given to the dopaminergic system, with
special focus on the dopamine D2-like (DRD2,
DRD3, DRD4) receptor subtype genes, with incon-
clusive results. Several factors could complicate
the molecular genetics of schizophrenia, including
genetic heterogeneity. To avoid genetic heteroge-
neity, it is crucial to study homogeneous popula-
tions such as, for example, the Portuguese
population (Schindler et al., 1999). Therefore, in
this study, we used this population to investigate
the involvement of polymorphisms at the DRD2
and DRD3 genes in schizophrenia by using asso-
ciation studies.
Using a dual genetic approach of association
analysis, HRR and TDT, we found no evidence of
association or linkage disequilibrium of the non-
functional TaqI-A polymorphism and functional
Ser311Cys polymorphism in the DRD2 gene and
schizophrenia. Similarly, the analysis of the hap-
lotypes did not show evidence of linkage disequi-
librium between these polymorphisms and
schizophrenia. Our findings for TaqI-A and
Ser311Cys polymorphisms do not corroborate pre-
vious findings obtained with case-control associa-
tion studies (Arinami et al., 1994, 1996) and
meta-analysis (Jonsson et al., 2003a). However,¨
they are in agreement with case-control association
studies carried out in different populations (Itoka-
wa et al., 1993; Sasaki et al., 1996; Tanaka et al.,
1996; Spurlock et al., 1998; Hori et al., 2001;
Himei et al., 2002). Other authors also have
obtained inconsistent results with association stud-
ies with the y141C InsyDel polymorphism at the
DRD2 gene (Li et al., 1998; Breen et al., 1999;
Jonsson et al., 1999; Himei et al., 2002).¨
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Taken together, the results of the analysis of
individual alleles, as well as the analysis of hap-
lotypes, appear to exclude a direct role of these
polymorphisms at the DRD2 gene in the pathogen-
esis of schizophrenia in our sample. Because the
Ser311Cys polymorphism, which is located in the
coding region, might be of physiological and
pathophysiological relevance to schizophrenia, fur-
ther investigations with this polymorphism in other
populations, as well as confirmatory studies in
populations already investigated, are needed.
The DRD3 gene has been the most investigated
gene for susceptibility to schizophrenia, and pub-
lished data with case–control association studies
have implicated the DRD3 gene as a risk factor
for this disorder (Kennedy et al., 1995; Mant et
al., 1994; Shaikh et al., 1996; Dubertret et al.,
1998; Jonsson et al., 2003b). Our results, obtained¨
with two powerful strategies of association (HRR
and TDT), indicate that the Ser9Gly polymorphism
in the first exon of the DRD3 gene is unlikely to
be involved in schizophrenia in our sample. Our
findings are in accordance with case–control asso-
ciation studies (Jonsson et al., 1993; Nimgaonkar¨
et al., 1993; Yang et al., 1993; Di Bella et al.,
1994; Chen et al., 1997), and with family-based
association studies (Macciardi et al., 1994; Roth-
schild et al., 1996; Prasad et al., 1999; Kremer et
al., 2000). Although negative, our results can only
exclude a very large effect of the investigated
polymorphism on schizophrenia in this population.
In addition, there is the possibility that molecular
defects in other genes that regulate the expression
of the DRD3 gene could be involved in the
pathogenesis of schizophrenia.
The DRD2 and DRD3 genes were screened for
polymorphisms related to schizophrenia. When
different methodologies of association were used,
the results failed to demonstrate a minor effect of
the TaqI-A, Ser311Cys and Ser9Gly polymor-
phisms in the predisposition to schizophrenia in
our sample. As in other studies, our sample did
not have enough power to detect an association
due to a gene with a small effect, and further
studies on a larger sample are required before
excluding DRD2 and DRD3 genes in the etiology
of schizophrenia in the Portuguese population.
Despite these negative results, the dopamine sys-
tem remains an important area of investigation in
schizophrenia. However, the dopamine system
alone is clearly insufficient to explain many bio-
logical factors underlying this disorder. Interactions
between dopamine and other neurotransmitter sys-
tems in complex neurocircuits may play a crucial
role in the pathogenesis of schizophrenia yielding
a multifactorial view of this disease (Carlsson et
al., 2001).
The strategy for future genetic studies on schiz-
ophrenia must use larger samples to increase sta-
tistical power. Furthermore, the development of
more powerful statistical analyses applying a best
definition of the clinical phenotype of the disease
by using endophenotypes will also be very impor-
tant to clarify the role of DRD2 and DRD3 genes
in schizophrenia.
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